Alluvi, known as BI 4744, presents a notable breakthrough in weight management therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates remarkable effectiveness in clinical studies, potentially https://alluvi-healthcare793405.polarisnewsblog.com/profile